Literature DB >> 10619234

A schema for estimating absorbed dose to organs following the administration of radionuclides with multiple unstable daughters: a matrix approach.

K A Hamacher1, G Sgouros.   

Abstract

The dosimetry of alpha particle emitters requires that all decays, including those of unstable intermediates be included in the calculation. Such calculations are complicated by the potential differential biologic distribution of each of the intermediates. In this work we present a formalism which will account for the known biodistribution factors of the daughters and the resulting effective biodistribution which will depend upon the site at which the parent radionuclide decays. The number of decays or cumulated activity of a daughter radionuclide present in a particular tissue is estimated using a probability matrix which describes the likelihood of daughter decay in a particular tissue as a function of the decay site of the parent. An example of three initial compartments is provided to illustrate the use of this formalism. Such modeling may be used to evaluate the feasibility of using radionuclides whose decay includes alpha-emitting intermediates. Model validation and refinement will require an assessment of the fate of free, alpha-emitting intermediates in various biological milieus.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10619234     DOI: 10.1118/1.598788

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  7 in total

Review 1.  Actinium-225 in targeted alpha-particle therapeutic applications.

Authors:  David A Scheinberg; Michael R McDevitt
Journal:  Curr Radiopharm       Date:  2011-10

Review 2.  Modelling and dosimetry for alpha-particle therapy.

Authors:  George Sgouros; Robert F Hobbs; Hong Song
Journal:  Curr Radiopharm       Date:  2011-07

Review 3.  Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.

Authors:  Mehran Makvandi; Edouard Dupis; Jonathan W Engle; F Meiring Nortier; Michael E Fassbender; Sam Simon; Eva R Birnbaum; Robert W Atcher; Kevin D John; Olivier Rixe; Jeffrey P Norenberg
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

Review 4.  Cancer radioimmunotherapy with alpha-emitting nuclides.

Authors:  Olivier Couturier; Stéphane Supiot; Marie Degraef-Mougin; Alain Faivre-Chauvet; Thomas Carlier; Jean-François Chatal; François Davodeau; Michel Cherel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

5.  MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.

Authors:  George Sgouros; John C Roeske; Michael R McDevitt; Stig Palm; Barry J Allen; Darrell R Fisher; A Bertrand Brill; Hong Song; Roger W Howell; Gamal Akabani; Wesley E Bolch; A Bertrand Brill; Darrell R Fisher; Roger W Howell; Ruby F Meredith; George Sgouros; Barry W Wessels; Pat B Zanzonico
Journal:  J Nucl Med       Date:  2010-01-15       Impact factor: 10.057

Review 6.  Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.

Authors:  Matthias Miederer; David A Scheinberg; Michael R McDevitt
Journal:  Adv Drug Deliv Rev       Date:  2008-04-23       Impact factor: 15.470

Review 7.  Imaging and dosimetry for radium-223: the potential for personalized treatment.

Authors:  Glenn D Flux
Journal:  Br J Radiol       Date:  2017-06-27       Impact factor: 3.039

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.